Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Progress towards the development of a HIV-1 gp41-directed vaccine.

McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WM, Joyce JG, Liang X, Miller MD, Pessi A, Shiver JW, Bogusky MJ.

Curr HIV Res. 2004 Apr;2(2):193-204. Review.

PMID:
15078183
2.

Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion.

Barbato G, Bianchi E, Ingallinella P, Hurni WH, Miller MD, Ciliberto G, Cortese R, Bazzo R, Shiver JW, Pessi A.

J Mol Biol. 2003 Jul 25;330(5):1101-15.

PMID:
12860131
3.

Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene.

Casimiro DR, Tang A, Chen L, Fu TM, Evans RK, Davies ME, Freed DC, Hurni W, Aste-Amezaga JM, Guan L, Long R, Huang L, Harris V, Nawrocki DK, Mach H, Troutman RD, Isopi LA, Murthy KK, Rice K, Wilson KA, Volkin DB, Emini EA, Shiver JW.

J Virol. 2003 Jul;77(13):7663-8.

4.

Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW.

J Virol. 2003 Jun;77(11):6305-13.

5.

HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.

McGaughey GB, Citron M, Danzeisen RC, Freidinger RM, Garsky VM, Hurni WM, Joyce JG, Liang X, Miller M, Shiver J, Bogusky MJ.

Biochemistry. 2003 Mar 25;42(11):3214-23.

PMID:
12641452
6.

Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.

Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, Citron MP, Danzeisen RC, Miller MD, Shiver JW, Keller PM.

J Biol Chem. 2002 Nov 29;277(48):45811-20. Epub 2002 Sep 16. Erratum in: J Biol Chem. 2003 Feb 14;278(7):5492..

7.

Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae.

Cook JC, Joyce JG, George HA, Schultz LD, Hurni WM, Jansen KU, Hepler RW, Ip C, Lowe RS, Keller PM, Lehman ED.

Protein Expr Purif. 1999 Dec;17(3):477-84.

PMID:
10600468
8.

Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast.

Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, Hurni WM, Joyce JG, Lehman ED, Markus HZ, Neeper MP, Schultz LD, Shaw AR, Jansen KU.

J Infect Dis. 1997 Nov;176(5):1141-5.

PMID:
9359711
9.

The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults.

Reuman PD, Kubilis P, Hurni W, Brown L, Nalin D.

Vaccine. 1997 Jul;15(10):1157-61.

PMID:
9269062
10.

Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.

Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR.

Pediatr Infect Dis J. 1996 Aug;15(8):687-92.

PMID:
8858673
11.

Duration of protection from clinical hepatitis A disease after vaccination with VAQTA.

Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, Brown L, Kuter BJ, Nalin DR.

J Med Virol. 1996 Jul;49(3):235-41.

PMID:
8818971
12.

Saliva and serum as diagnostic media for antibody to hepatitis A virus in adults and in individuals who have received an inactivated hepatitis A vaccine.

Laufer DS, Hurni W, Watson B, Miller W, Ryan J, Nalin D, Brown L.

Clin Infect Dis. 1995 Apr;20(4):868-71.

PMID:
7795087
13.

Characterization and evaluation of a recombinant hepatitis B vaccine expressed in yeast defective for N-linked hyperglycosylation.

Kniskern PJ, Hagopian A, Burke P, Schultz LD, Montgomery DL, Hurni WM, Ip CY, Schulman CA, Maigetter RZ, Wampler DE, et al.

Vaccine. 1994 Aug;12(11):1021-5.

PMID:
7975842
14.

Sensitive assays for hepatitis A antibodies.

Miller WJ, Clark W, Hurni W, Kuter B, Schofield T, Nalin D.

J Med Virol. 1993 Nov;41(3):201-4.

PMID:
8263501
15.

Anti-hepatitis A in the general population and in hepatitis A vaccinees using saliva and serum as diagnostic media.

Hurni WM, Laufer D, Miller WJ, Ryan J, Watson B.

Ann N Y Acad Sci. 1993 Sep 20;694:289-92. No abstract available.

PMID:
8215069
17.
18.
19.

Isolation of multiple biologically and chemically diverse species of epidermal growth factor.

Riemen MW, Wegrzyn RJ, Baker AE, Hurni WM, Bennett CD, Oliff A, Stein RB.

Peptides. 1987 Sep-Oct;8(5):877-85.

PMID:
3501577
20.

Viral enhancement and interference induced in cell culture by hepatitis A virus: application to quantitative assays for hepatitis A virus.

Hurni WM, Miller WJ, McAleer WJ, Provost PJ, Hilleman MR.

Proc Soc Exp Biol Med. 1984 Jan;175(1):84-7.

PMID:
6320206
21.

Automated cytopathic effect (CPE) assays.

McAleer WJ, Miller WJ, Hurni WM, Machlowitz RA, Hilleman MR.

J Biol Stand. 1983 Jul;11(3):241-6.

PMID:
6885830
22.

High-resolution flow-zonal centrifuge system.

McAleer WJ, Hurni W, Wasmuth E, Hilleman MR.

Biotechnol Bioeng. 1979 Feb;21(2):317-21.

PMID:
427264
23.

Cytogenetic and other effects of 144Ce in Chinese hamsters. LF-41.

Brooks AL, Jones RK, Hurni WM, McClellan RO, Sturbaum B.

Fission Prod Inhal Proj. 1969 Nov:192-202. No abstract available.

PMID:
5310176

Supplemental Content

Support Center